New data now available on the speed, accuracy and advantages of the Accelerate Pheno™ system
Jun 15, 2017
TUCSON, Ariz., (June 14, 2017) — Accelerate Diagnostics, Inc. showcased new data presented at ASM Microbe 2017 on the potential clinical and workflow benefits of faster susceptibility results using the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit.
The data comes from external studies across 11 healthcare institutions representing 1,300 samples, and compares the performance of the system and kit to current testing methods. The studies also include new early stage research on potential whole blood applications.
To review summaries of the new performance and research data, or the complete studies, visit: http://acceleratediagnostics.com/asmdata.
Note: The data presented at ASM Microbe 2017 includes information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures. Certain uses of the devices included in the data from these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies. See product labeling for instructions for use, warnings, and limitations specific to each product and region.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company’s Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit were recently cleared by the FDA for antimicrobial susceptibility testing direct from positive blood culture samples. The solution leverages proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. To learn more, visit axdx.com.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
+1 520 365-3100
- Accelerate Diagnostics, Inc. announced the election of Charles Watts, M.D. to the company’s board of directors. His appointment is effective November 14, 2017.
Nov 16, 2017
- New from LabRoots: Dr. Margie Morgan to present on the impact of fast phenotypic susceptibility results to laboratory workflow and patient outcomes
Nov 09, 2017